Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Ahren, Bo, Atkin, Stephen L, Charpentier, Guillaume, Warren, Mark L, Wilding, John PH ORCID: 0000-0003-2839-8404, Birch, Sune, Holst, Anders Gaarsdal and Leiter, Lawrence A (2018) Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. DIABETES OBESITY & METABOLISM, 20 (9). 2210 - 2219.

Access the full-text of this item by clicking on the Open Access link.

Item Type:	Article
Uncontrolled Keywords:	BMI, gastrointestinal adverse events, GLP-1 analogue, GLP-1 based therapy, nausea, type 2, vomiting, weight control, weight loss
Depositing User:	Symplectic Admin
Date Deposited:	20 Jul 2018 10:20
Last Modified:	22 Jan 2021 16:10
DOI:	10.1111/dom.13353
Open Access URL:	https://onlinelibrary.wiley.com/doi/epdf/10.1111/d...
Related URLs:	Author
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3023979